Century Therapeutics, Inc.
IPSC
$2.21
$0.094.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 109.16M | 113.34M | 114.13M | 114.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 109.16M | 113.34M | 114.13M | 114.90M |
| Cost of Revenue | 86.19M | 95.66M | 105.34M | 110.04M | 110.40M |
| Gross Profit | -86.19M | 13.50M | 8.00M | 4.09M | 4.50M |
| SG&A Expenses | 28.91M | 29.16M | 31.29M | 32.80M | 33.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.10M | 124.82M | 136.63M | 142.85M | 143.71M |
| Operating Income | -115.10M | -15.66M | -23.29M | -28.72M | -28.81M |
| Income Before Tax | -107.85M | -9.64M | -24.70M | -21.51M | -20.16M |
| Income Tax Expenses | -68.00K | -68.00K | 1.78M | 1.77M | 1.79M |
| Earnings from Continuing Operations | -107.78 | -9.57 | -26.48 | -23.28 | -21.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.78M | -9.57M | -26.48M | -23.28M | -21.95M |
| EBIT | -115.10M | -15.66M | -23.29M | -28.72M | -28.81M |
| EBITDA | -102.21M | -2.56M | -10.42M | -15.68M | -15.51M |
| EPS Basic | -1.11 | -0.11 | -0.31 | -0.28 | -0.28 |
| Normalized Basic EPS | -0.68 | -0.05 | -0.10 | -0.13 | -0.13 |
| EPS Diluted | -1.11 | -0.11 | -0.32 | -0.29 | -0.29 |
| Normalized Diluted EPS | -0.68 | -0.05 | -0.10 | -0.13 | -0.14 |
| Average Basic Shares Outstanding | 453.46M | 346.01M | 344.14M | 342.38M | 338.23M |
| Average Diluted Shares Outstanding | 453.46M | 346.09M | 344.21M | 342.45M | 338.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |